Shehab Mohamed: Real-World Evidence on Maternal and Neonatal Outcomes in ITP
Shehab Mohamed, Hematologist at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Health Science Reports, adding:
“Here we go!
Newly published study in Health Science Reports:
Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five-Year Single-Center Cross-Sectional Study
At our center, we always strive to reflect on our real-world clinical experience and translate it into evidence that can help improve patient care. This study represents our 5-year experience managing pregnant patients with immune thrombocytopenia (ITP) at Hamad Medical Corporation, Qatar.
Key findings:
- Most pregnancies were uncomplicated
- Maternal complications occurred in 19.8% of cases
- Neonatal complications occurred in 12.4% of cases
- Pregnancy-onset ITP was associated with higher complication rates than pre-pregnancy ITP
- Steroids and IVIG remained effective first-line therapies
- Selected refractory cases were successfully managed with thrombopoietin receptor agonists
One particularly reassuring observation was that our maternal and neonatal outcomes closely mirrored those reported in contemporary international real-world studies, supporting the quality of care delivered in our center and reinforcing the generalizability of current evidence to our diverse Middle Eastern population.
These findings highlight the importance of early recognition, multidisciplinary collaboration, and individualized management in optimizing outcomes for both mothers and newborns.
Grateful to all co-authors, collaborators, and patients who contributed to this work.”
Title: Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five-Year Single-Center Cross-Sectional Study
Authors: Sara Elkorashi, Hassan Magboul, Abdulrahman F. Al-Mashdali, Mohammed Alnajjar, Naela AlMallahi, Elmustafa Abdalla, Dina Sameh Soliman, Sara Aldali, Manar Elsheikh, Honar Cherif, Shehab F. Mohamed
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 3, 2026, 08:57Nita Radhakrishnan: Moving Beyond Half-Life in Hemophilia Prophylaxis at NHU 2026
-
Aug 3, 2026, 08:47Neetu Gaur: Why Platelets Matter More Than You Think
-
Aug 3, 2026, 07:17Filippo Cademartiri: Treating Atherosclerosis Rather Than Its Probability
-
Aug 3, 2026, 03:18Ajay Samkaria: Every Unexpected Antibody Tells a Story
-
Aug 3, 2026, 03:06Abdul Mannan: The Most Important Tube in the FXIII Assay
-
Aug 3, 2026, 02:29Herman Sandeep Prakasam: Who Is Missing Anticoagulation?
-
Aug 2, 2026, 23:07Akshat Jain: Redefining Hemophilia Readiness in Mexico
-
Aug 2, 2026, 16:24Satish Medakkar: The Importance of Early Recognition in Atypical Hemolytic Uremic Syndrome
-
Aug 2, 2026, 16:07Mirjavad Mammadov: Understanding the Thrombotic Paradox of Heparin Therapy